Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
hypnotic orexin receptor antagonist |
| gptkbp:ATCCode |
N05CM25
|
| gptkbp:brand |
gptkb:Dayvigo
|
| gptkbp:CASNumber |
1369764-02-2
|
| gptkbp:developer |
gptkb:Eisai
|
| gptkbp:eliminationHalfLife |
17 to 19 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:FDAApproved |
December 2019
|
| gptkbp:hasMolecularFormula |
C22H20F2N4O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
lemborexant
|
| gptkbp:KEGGID |
D11077
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dual orexin receptor antagonist
|
| gptkbp:metabolism |
gptkb:liver_(CYP3A)
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
58919616 71545873 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
headache somnolence |
| gptkbp:synonym |
E2006
|
| gptkbp:UNII |
6Y7TQ9OE1P
|
| gptkbp:usedFor |
insomnia
|
| gptkbp:bfsParent |
gptkb:YFL-787
gptkb:Dayvigo |
| gptkbp:bfsLayer |
7
|